Collplant Biotechnologies (NASDAQ:CLGN) specializes in regenerative and aesthetic medicine by leveraging its proprietary plant-based rhCollagen technology. This innovative approach aims at developing tissue repair products, bioinks for 3D bioprinting, and dermal fillers. Their groundbreaking projects include research into life-saving organs and skin regeneration treatments. The company's goal is to revolutionize medical treatments and improve patient outcomes through sustainable, scalable, and high-purity collagen production. Collplant is committed to expanding its portfolio of regenerative medicine products while focusing on strategic partnerships and technological advancements to meet the growing global demand.